Study on the Clinical Value of miR-122 and miR-449a Detection in ER-Positive Breast Cancer Patients Treated with Tamoxifen
Objective:To analyze the clinical value of minimal RNA(miR)-122 and miR-449a detection in estrogen receptor(ER)-positive breast cancer patients treated with adjuvant tamoxifen.Methods:258 ER-positive breast cancer patients were selected,and all patients treated with tamoxifen.The relationship between the expression of serum exosomal miR-122 and miR-449a and the clinicopathological characteristics of patients were analyzed.5 years after follow-up,the survival rate was analyzed by Kaplan-Meier curve,and the influencing factors was analyzed by multivariate Cox regression.Results:The serum exosomal miR-122 of ER positive breast cancer patients with histological grade 3,TNM stage Ⅲ,axillary lymph node metastasis and high expression of Ki-67 before treatment was higher than that of histological grade 1-2,TNM stage Ⅰ/Ⅱ,no axillary lymph node metastasis and low expression of Ki-67,and miR-449a was lower(P＜0.05).The median overall survival(OS)of miR-122 high expression group was lower than that of miR-122 low expression group(P＜0.05).The median OS of miR-449a low expression group was lower than that of miR-449a high expression group(P＜0.05).Cox regression analysis showed that TNM stage Ⅲ,high expression of Ki-67(≥ 14％),high expression of miR-122 and low expression of miR-449a were independent risk factors for poor prognosis of tamoxifen adjuvant therapy in ER-positive breast cancer patients(P＜0.05).Conclusion:The expression levels of serum exosomal miR-122 and miR-449a in ER-positive breast cancer patients are correlated with TNM stage Ⅲ and high expression of Ki-67,the high expression of miR-122 and the low expression of miR-449a are independent risk factors affecting the 5-year survival of patients,It is expected to be an important marker for predicting the prognosis of tamoxifen adjuvant therapy.
ER-positive breast cancerTamoxifenmiR-122miR-449aPrognosis
万方数据
维普
